Infecção por sars-cov-2 em pacientes submetidos à transplante cardíaco: uma revisão integrativa sobre o novo desafio para a cardiologia
DOI:
https://doi.org/10.11606/issn.1679-9836.v102i5e-209909Palavras-chave:
COVID-19, Transplante cardíaco, Terapia de imunossupressãoResumo
Introdução: O SARS-CoV-2 é um vírus de alta disseminação cujo principal alvo de infecção é o sistema respiratório, porém, ao desencadear uma resposta imunológica exacerbada, sinalizada pela tempestade de citocinas, pode provocar lesões em múltiplos órgãos. Diante disso, este estudo busca reunir evidências que avaliem a vulnerabilidade de pacientes transplantados às manifestações clínicas do COVID-19, considerando o manejo do regime de imunossupressão e os efeitos das interações medicamentosas, na tentativa de promover estratégias adequadas de gerenciamento terapêutico. Desenvolvimento: Trata-se de uma revisão integrativa da literatura, realizada em março de 2023, na qual foram selecionados 6 artigos. Pacientes submetidos a transplantes cardíacos, devido ao quadro de imunossupressão, apresentam maior tendência em apresentar doenças cardiovasculares. A contaminação por SARS-CoV-2 aumenta significativamente o risco de complicações, e estabelece um desafio: equilibrar o regime de imunossupressores com a terapia antiviral, tendo em vista as interações medicamentosas. Considerações finais: O uso de imunossupressores parece ser responsável por um curso mais brando da COVID-19 em pacientes submetidos a transplante cardíaco, pela atenuação da tempestade de citocinas. Apesar disso, ainda há risco de gravidade da COVID-19, sendo necessário priorizar o manejo com terapias antivirais que melhor se adaptem às medicações imunossupressoras.
Downloads
Referências
Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. [Internet]. 2020;109(5):531-8. https://doi.org/10.1007/s00392-020-01626-9
Xiong S, Liu L, Lin F, Shi J, Han L, Liu H, et al. Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study. BMC Infect Dis. 2020;20(1):787. https://doi.org/10.1186/s12879-020-05452-2
Tschopp J, L’Huillier AG, Mombelli M, Mueller NJ, Khanna N, Garzoni C, et al. First experience of SARS‐CoV‐2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. Am J Transplant. 2020;20(10):2876-82. https://doi.org/10.1111/ajt.16062
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020;323(13):1239-42. https://doi.org/10.1001/jama.2020.2648
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. https://doi.org/10.1016/s0140-6736(20)30566-3
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 2020;395(10223):497-506. Available from: https://doi.org/10.1016/S0140-6736(20)30183-5
Yi SG, Rogers AW, Saharia A, Aoun M, Faour R, Abdelrahim M, et al. Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center. Transplantation. 2020;104(11):2208-14. https://doi.org/10.1097%2FTP.0000000000003339
Hartmann C, Miggiolaro AFR dos S, Motta J da S, Baena Carstens L, Busatta Vaz De Paula C, Fagundes Grobe S, et al. The Pathogenesis of COVID-19 Myocardial Injury: An Immunohistochemical Study of Postmortem Biopsies. Front Immunol. [Internet]. 2021;12:748417. Available from: https://doi.org/10.3389%2Ffimmu.2021.748417
Kulasinghe A, Liu N, Tan CW, Monkman J, Sinclair JE, Bhuva DD, et al. Transcriptomic profiling of cardiac tissues from SARS‐CoV ‐2 patients identifies DNA damage. Immunology. 2023;168:403-19 https://doi.org/10.1111/imm.13577
Aslam S, Mehra MR. COVID-19: Yet another coronavirus challenge in transplantation. J Heart Lung Transplant. 2020;39(5):408-9. https://doi.org/10.1016/j.healun.2020.03.007
Caraffa R, Bagozzi L, Fiocco A, Bifulco O, Nadali M, Ponzoni M, et al. Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience. Europ J Cardio-Thoracic Surg. 2020;58(5):899-906. https://doi.org/10.1093/ejcts/ezaa323
Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID‐19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant. 2020;20(7):1800-8. https://doi.org/10.1111/ajt.15941
Bösch F, Börner N, Kemmner S, Lampert C, Jacob S, Koliogiannis D, et al. Attenuated early inflammatory response in solid organ recipients with COVID‐19. Clin Transplant. 2020;34:e14027. https://doi.org/10.1111%2Fctr.14027
Singhvi A, Barghash M, Lala A, Mitter SS, Parikh A, Oliveros E, et al. Challenges in heart transplantation during COVID-19: A single-center experience. J Heart Lung Transplant. 2020;39(9):894-903. https://doi.org/10.1016/j.healun.2020.06.015
Costa IBS da S, Bittar CS, Rizk SI, Araújo Filho AE de, Santos KAQ, Machado TIV, et al. The Heart and COVID-19: What Cardiologists Need to Know. Arq Bras Cardiol [Internet]. 2020;114(5):805-16. https://doi.org/10.36660/abc.20200279
Molnar MZ, Bhalla A, Azhar A, Tsujita M, Talwar M, Balaraman V, et al. Outcomes of critically ill solid organ transplant patients with COVID‐19 in the United States. Am J Transplant. 2020;20(11):3061-71. https://doi.org/10.1111/ajt.16280
Lima B, Gibson GT, Vullaganti S, Malhame K, Maybaum S, Hussain ST, et al. COVID‐19 in recent heart transplant recipients: Clinicopathologic features and early outcomes. Transplant Infect Dis. 2020;22(5). https://doi.org/10.1111/tid.13382
Mirjalili M, Shafiekhani M, Vazin A. Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen. Therapeut Clin Risk Manag. 2020;16:617-29. https://doi.org/10.2147%2FTCRM.S256246
Chen TY, Farghaly S, Cham S, Tatem LL, Sin JH, Rauda R, et al. COVID‐19 pneumonia in kidney transplant recipients: Focus on immunosuppression management. Transplant Infect Disease. 2020;22(5). https://doi.org/10.1111%2Ftid.13378
Decker A, Welzel M, Laubner K, Grundmann S, Kochs G, Panning M, et al. Prolonged SARS‐CoV‐2 shedding and mild course of COVID‐19 in a patient after recent heart transplantation. Am J Transplant. 2020;20(11):3239-45. https://doi.org/10.1111%2Fajt.16133
Latif F, Farr MA, Clerkin KJ, Habal MV, Takeda K, Naka Y, et al. Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. JAMA Cardiology. 2020;5(10):1165. https://doi.org/10.1001/jamacardio.2020.2159
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet [Internet]. 2020;395(10229):1033-4. https://doi.org/10.1016/S0140-6736(20)30628-0
Ren ZL, Hu R, Wang ZW, Zhang M, Ruan YL, Wu ZY, et al. Epidemiological and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: a descriptive survey report. J Heart Lung Transplant. 2020 Mar; https://doi.org/10.1016/j.healun.2020.03.008
DeFilippis EM, Farr MA, Givertz MM. Challenges in heart transplantation in the era of COVID-19. Circulation. 2020;141(25):2048-51. https://doi.org/10.1161/circulationaha.120.047096
Rivinius R, Kaya Z, Schramm R, Boeken U, Provaznik Z, Heim C, et al. COVID-19 among heart transplant recipients in Germany: a multicenter survey. Clin Res Cardiol. 2020;109(12):1531-9. https://doi.org/10.1007%2Fs00392-020-01722-w
Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6):e79. https://doi.org/10.3346/jkms.2020.35.e79
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England J Med. 2020;382(19):1787-99; https://doi.org/10.1056/nejmoa2001282
Horby P W, Mafham M, Bell J L, Linsell L, Staplin N, Emberson J, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet [Internet]. 2020;396(10259):1345-52. https://doi.org/10.1016/S0140-6736(20)32013-4
Afsaneh Vazin, Farbod Shahabinezhad, Niknam T, Seyed Mahmood Tara, Elham Haem, Parviz Mardani, et al. Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand? Virol J. 2021;18(1). https://doi.org/10.1186%2Fs12985-021-01700-2
Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, Jiang J. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents. 2020;56(3):106114. https://doi.org/10.1016/j.ijantimicag.2020.106114
Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet [Internet]. 2020;395(10238). https://doi.org/10.1016/s0140-6736(20)31042-4
Fontana F, Alfano G, Mori G, Amurri A, Lorenzo T, Ballestri M, et al. Covid‐19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine. Am J Transplant. 2020 Apr 23; https://doi.org/10.1111/ajt.15935
Shin BH, Everly MJ, Zhang H, Choi J, Vo A, Zhang X, et al. Impact of Tocilizumab (Anti–IL-6R) treatment on immunoglobulins and Anti-HLA Antibodies in kidney transplant patients with chronic antibody-mediated rejection. transplantation [Internet]. 2020;104(4):856-63. https://journals.lww.com/transplantjournal/FullText/2020/04000/Impact_of_Tocilizumab__Anti_IL_6R__Treatment_on.30.aspx DOI: 10.1097/TP.0000000000002895
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407-18. https://doi.org/10.1016/s2213-2600(21)00331-3
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021; 384:795-807. https://doi.org/10.1056/nejmoa2031994
Satarker S, Tom AA, Shaji RA, Alosious A, Luvis M, Nampoothiri M. JAK-STAT pathway inhibition and their implications in COVID-19 therapy. Postgraduate Medicine. 2021;133(5):489-507. https://doi.org/10.1080/00325481.2020.1855921
Rochwerg B, Agoritsas T, Lamontagne F, Leo YS, Macdonald H, Agarwal A, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. https://doi.org/10.1136/bmj.m3379
Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-93. https://doi.org/10.1126/science.abl4784
Mahase E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375:n2713. https://doi.org/10.1136/bmj.n2713
Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J., et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198:105252. https://doi.org/10.1016/j.antiviral.2022.105252
Tang Y, Li Y, Song T. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: a review of immunosuppressant adjustment strategies. 2023;14. https://doi.org/10.3389%2Ffimmu.2023.1150341
Devresse A, Sébastien Briol, De Greef J, Lemaitre F, Boland L, Haufroid V, et al. Safety, Efficacy, and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected With SARS-CoV-2. Kidney Int Rep. 2022;7(11):2356-63. https://doi.org/10.1016%2Fj.ekir.2022.08.026
Hedvat J, Lange NW, Salerno DM, DeFilippis EM, Kovac D, Corbo H, et al. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era. Am J Transplant. 2022;22(11):2682-8. https://doi.org/10.1111/ajt.17140
Salerno DM, Jennings DL, Lange NW, Kovac D, Shertel T, Chen JK, et al. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. Am J Transplant. 2022;22(8):2083-8. https://doi.org/10.1111/ajt.17027
Stawiarski K, Avery R, Strout S, Umapathi P. Risks of paxlovid in a heart transplant recipient. J Heart Lung Transplant. 2023;42(1):30-2. https://doi.org/10.1016%2Fj.healun.2022.08.029
Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65(5):e02428-20. https://doi.org/10.1128/aac.02428-20
Dhand A, Okumura K, Ohira S, Kapur R, Wolfe K, Nishida S. Molnupiravir for Treatment of COVID-19 in Solid Organ Transplant Recipients. Transplantation. 2023;107(6):e182-e183. https://doi.org/10.1097/tp.0000000000004588
Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? European Heart J. 2020;41(19):1801-3. https://doi.org/10.1093/eurheartj/ehaa235
Kanaan CN, Iskandar JP, Gad MM, Kondoleon NP, Mirzai S, Hsich EM, et al. Outcomes Associated With COVID-19 Hospitalization in Heart Transplantation Patients. Transplantation Proceedings. 2022;54(10):2688-91. https://doi.org/10.1016/j.transproceed.2022.06.002
Mendoza MA, Nischal Ranganath, Supavit Chesdachai, Yetmar ZA, Razonable RR, Omar Abu Saleh. Immunomodulators for severe coronavirus disease‐2019 in transplant patients: do they increase the risk of secondary infection? 2023;25(2):e14050. https://doi.org/10.1111/tid.14050
Peters LL, Raymer DS, Pal JD, Ambardekar AV. Association of COVID-19 vaccination with risk of COVID-19 infection, hospitalization, and death in heart transplant recipients. JAMA Cardiol. 2022;7(6):651-4. https://doi.org/10.1001/jamacardio.2022.0670
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2023 Bruno Galdino Moreira, Andreza Alverga de Lima , Maria Alice Vieira Melo de Lima, Francisco Guilherme Leite Linhares de Sá, Rodolfo de Abreu Carolino, Marta Lígia Vieira Melo
Este trabalho está licenciado sob uma licença Creative Commons Attribution-ShareAlike 4.0 International License.
